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Abstract   
Background 
The delivery of ubiquitinated proteins to the proteasome for degradation is a key step in the 
regulation of the ubiquitin-proteasome pathway, yet the mechanisms underlying this step are not 
understood in detail. The Rad23 family of proteins is known to bind ubiquitinated proteins 
through its two ubiquitin-associated (UBA) domains, and may participate in the delivery of 
ubiquitinated proteins to the proteasome through docking via the Rad23 ubiquitin-like (UBL) 
domain.  
 
Results 
In this study, we investigate how the interaction between the UBL and UBA domains may 
modulate ubiquitin recognition and the delivery of ubiquitinated proteins to the proteasome by 
autoinhibition. We have explored a competitive binding model using specific mutations in the 
UBL domain. Disrupting the intramolecular UBL-UBA domain interactions in HHR23A indeed 
potentiates ubiquitin-binding. Additionally, the analogous surface on the Rad23 UBL domain 
overlaps with that required for interaction with both proteasomes and the ubiquitin ligase Ufd2. 
We have found that mutation of residues on this surface affects the ability of Rad23 to deliver 
ubiquitinated proteins to the proteasome.  
 
Conclusions 
We conclude that the competition of ubiquitin-proteasome pathway components for surfaces on 
Rad23 is important for the role of the Rad23 family proteins in proteasomal targeting. 
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Background               
Targeted protein degradation by the ubiquitin-proteasome pathway is a key means of regulating a 
wide variety of cellular processes, ranging from cell cycle progression [1] to antigen presentation 
[2]. In this pathway, an enzymatic cascade covalently attaches ubiquitin to a lysine residue on 
substrate proteins. The subsequent conjugation of more ubiquitin moieties, each typically linked 
through Lys48 of ubiquitin, results in a polyubiquitin chain that directs substrate proteins to the 
proteasome where they are degraded (reviewed in [3]). The importance of this proteasome-
targeting step was demonstrated by experiments showing that the artificial localization of 
proteins to the proteasome is sufficient to cause their degradation [4].  
 
Recent work indicates that ubiquitin receptors, which bind ubiquitin but are not intrinsic subunits 
of the proteasome, facilitate the docking of ubiquitinated substrates to the proteasome [5-8]. The 
best-studied of these receptors are the UBL-UBA proteins and include three groups: 
Rad23/HHR23A/HHR23B, Dsk2/PLIC1/PLIC2, and Ddi1. Rad23, for example, has been shown 
to play a role in the targeting of the cyclin-dependent kinase inhibitor Sic1 to the proteasome [5], 
and Ddi1 mediates degradation of the Ho endonuclease [9] and of the F-box protein Ufo1 [10].  
 
Each Rad23 family member has a ubiquitin-like (UBL) domain that binds proteasomes [11-13] 
as well as two ubiquitin-associated (UBA) domains that bind ubiquitin [14-17]. The structure of 
HHR23A has been solved by NMR spectroscopy [18, 19], which revealed that the UBL and 
UBA domains interact intramolecularly in a highly dynamic manner, as each UBA domain 
competes for an overlapping UBL domain surface [18]. The UBL domain of HHR23A has also 
been shown to bind to proteasomal subunit S5a [12], and notably, the UBL surface bound by S5a 
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overlaps significantly with that bound by the UBA domains [18]. As with the UBL domain of 
HHR23A, the UBA domains also have multifunctional surfaces: specifically, the UBL- and 
ubiquitin-binding surfaces overlap. The binding of S5a or ubiquitin to HHR23A thus disrupts the 
intramolecular UBL-UBA interactions and drives HHR23A into an open conformation [18, 20]. 
We hypothesize that these conformational changes, governed by UBL-UBA interactions, are 
important for HHR23A function.  
 
To determine how UBL and UBA domain interactions contribute to Rad23/HHR23A function in 
ubiquitin-mediated proteolysis, we identified mutations that disrupt UBL-UBA binding, then 
tested the ability of the mutant proteins to bind components of the ubiquitin-proteasome pathway 
and to mediate delivery of a ubiquitinated substrate to the proteasome. Our results show that the 
interactions of the UBL and UBA domains with each other and with other proteins are 
interdependent, and that modulating proteasome-binding is important for the role of 
Rad23/HHR23 in proteasomal targeting.  
 
Results  
Identification of UBL mutations that reduce UBA-binding 
To identify UBL mutations that affect UBA-binding, we established an affinity column 
chromatography assay using resin-bound UBA domains and mobile ligands. To demonstrate that 
our assay can distinguish proteins based on their relative affinities for the UBA domains, control 
experiments were performed with ubiquitin and SUMO. Both proteins are similar in size and 
structure to the UBL domain but ubiquitin binds the UBA domains whereas SUMO does not [14, 
15, 21]. Equal amounts of hemagglutinin-tagged SUMO (HA-SUMO), polyhistidine-tagged 
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ubiquitin (Ub-His), and FLAG-tagged wild-type HHR23A UBL (UBL-FLAG) were mixed and 
loaded onto the GST-HHR23A~∆UBL column. HA-SUMO eluted from the column first, 
followed by the wild-type UBL. Ub-His eluted from the column only when the salt concentration 
in the running buffer was increased from 150mM to 400mM (Additional file 1A). Therefore, the 
order in which ubiquitin, UBL and SUMO eluted from the GST-HHR23A~∆UBL column 
corresponded to their relative ability to interact with UBA domains. To confirm that the 
difference in retention time of each protein on the column is specifically due to their respective 
abilities to bind the UBA domains, we conducted a similar control experiment using a 
glutathione-sepharose column charged with GST only. HA-SUMO, Ub-His and UBL-FLAG all 
eluted from the GST column simultaneously (Additional file 1B).  
 
To abrogate UBL-UBA binding, we mutated residues located on the UBA-binding surface of 
HHR23A [18] that are conserved in the other human homolog of Rad23, HHR23B. We also 
considered data from previous structural studies of HHR23A, which showed that UBL-UBA 
binding is mediated mainly by hydrophobic interactions and that specificity is conferred by the 
topology of the binding surfaces [18, 22]. The UBA-binding surface of the UBL domain is 
predominantly hydrophobic with a few basic regions [23] whereas the UBL-binding surface of 
the UBA domains are similarly hydrophobic but with a few acidic residues [20]. Glutamic acid 
mutations in the UBA-binding surface would cause electrostatic repulsion against the UBA 
domains and thus be effective at disrupting the UBL-UBA interaction. Therefore, we mutated 
L10, K47 and T77 of HHR23A to glutamic acid, individually or in combination (as indicated in 
Figure 1A).   
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To determine the affinity of these UBL mutants for UBA domains relative to wild-type UBL, 
UBL domain constructs were mutated accordingly and tested in our affinity column 
chromatography assay. As shown in Figure 1C, wild-type UBL began eluting off the column in 
fractions 18-20 and the elution profile of the K47A UBL mutant is identical to that of the wild-
type UBL domain. In contrast, the L10E/K47E double mutant began to elute in fraction 12 and 
the K47/T77E and K47E mutants in fraction 14. These data indicate that the glutamic acid UBL 
mutants, but not the alanine mutant, have a reduced ability to bind the UBA domains relative to 
the wild-type UBL.   
 
HHR23A bearing UBA-binding mutations in the UBL domain show enhanced binding to 
polyubiquitin 
The ubiquitin-binding surface on the UBA domains overlaps significantly with that involved in 
binding the UBL domain [19, 20]. Disrupting the intramolecular UBL-UBA domain interactions 
is expected to make the UBA domains more accessible to ubiquitin. We probed the affinity of 
mutant HHR23A protein for ubiquitin binding by assessing the extent to which each competed 
with resin-bound GST-HHR23A for polyubiquitin-binding. As shown in Figure 2A, 
polyubiquitin bound GST-HHR23A but not GST alone. As increasing amounts of untagged 
wild-type HHR23A was used as a competitor, the amount of polyubiquitin bound to GST-
HHR23A decreased. As expected, HHR23A~∆UBL competed with GST-HHR23A more 
effectively than wild-type HHR23A for polyubiquitin-binding whereas the HHR23A 
L198A/L355A double mutant, in which the UBA domains are unfolded and thus unable to bind 
ubiquitin [14, 20], did not compete at all.  
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The HHR23A UBL mutants were then tested as competitors in the GST-pulldown competition 
assay. All the bands in the polyubiquitin Western blot are conjugates of free ubiquitin, but rather 
than quantify a smear, we quantified the specific band corresponding to tetra-ubiquitin, which is 
the minimum length required for proteasomal targeting [24]. The amount of tetra-ubiquitin 
bound to GST-HHR23A in the presence of competitor was then expressed as a percentage of the 
amount of tetra-ubiquitin bound in the absence of competitor (Figure 2B). When wild-type 
HHR23A was used as a competitor, the amount of polyubiquitin bound to GST-HHR23A 
decreased from 87% to 39% as the ratio of competitor to GST-HHR23A was increased from 0.2 
to 1. As expected, HHR23A~∆UBL was a more effective competitor than wild-type HHR23A, 
with only 75% of ubiquitin bound at a competitor to GST-HHR23A ratio of 0.2, and only 29% 
bound at a ratio of 1. This result is consistent with previous findings that HHR23A lacking the 
UBL domain exhibits higher affinity for polyubiquitin chains compared to the full-length protein 
[25]. 
 
In contrast, the UBA domain double mutant L198A/L355A did not compete with GST-HHR23A 
for polyubiquitin binding. The UBL domain mutants L10E/K47E and K47E/T77E, which 
showed reduced UBA-binding (Figure 1C), competed for ubiquitin-binding more effectively 
than wild-type HHR23A, and to a similar extent as HHR23A~∆UBL. Our results demonstrate 
that UBL-UBA domain interactions reduce HHR23A’s ability to bind ubiquitin. They also 
provide evidence that the enhanced polyubiquitin-binding of HHR23A~∆UBL relative to wild-
type HHR23A is due to loss of auto-inhibition mediated by UBL-UBA domain interactions.  
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UBA-binding mutations in the Rad23 UBL domain impair proteasome-binding  
In addition to regulating ubiquitin-binding, UBL-UBA domain interactions could also affect 
proteasome-binding such that it is enhanced when the HHR23 proteins are bound to 
ubiquitinated proteins. For this hypothesis to be true, the proteasome must bind a surface on the 
UBL domain overlapping with that which binds the UBA domains. Indeed, the UBL domain is 
necessary and sufficient for interaction with the proteasome [11] and the binding of HHR23A to 
S5a disrupts UBL-UBA domain binding [18]. Therefore, we tested whether the UBA-binding 
surface of HHR23 family proteins is required for proteasome interaction. 
 
Just as ubiquitin itself binds multiple subunits of the proteasome, including Rpn10/S5a and 
Rpt6/S6’ [26, 27], so could the Rad23/HHR23 proteins. Therefore, we tested the ability of our 
UBL mutants, which are defective in UBA-binding, to interact with purified proteasomes instead 
of with specific subunits. We also used the budding yeast Saccharomyces cerevisiae as a model 
system as it is better-characterized and easier to manipulate genetically.  
 
L10, K47 and T77 in HHR23A correspond to F9, K43 and S73 in Rad23 respectively, as 
determined by sequence alignment. We mutated these Rad23 residues to glutamic acid as we had 
done for HHR23A. To test proteasome-binding, we used recombinant, purified 32P-labelled 
Rad23 proteins and purified yeast proteasomes in a electrophoretic mobility shift assay. In the 
presence of proteasomes, the mobility of wild-type Rad23, but not Rad23~∆UBL, decreased, as 
indicated by the arrowheads in Figure 3. The intensity of the shifted band is an indicator of the 
amount of proteasome-bound Rad23, which increased as more proteasome was titrated into the 
reaction. With the exception of the S73E mutant, the Rad23 UBL mutants showed no detectable 
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interaction with the proteasome in vitro. This finding provides strong evidence that Rad23 binds 
the proteasome via the same surface that is responsible for S5a- and UBA-binding in HHR23A.  
 
Mutation of the Rad23 UBL domain impairs interactions with Ufd2  
In addition to the proteasome, the Rad23/HHR23A UBL domain binds other proteins involved in 
ubiquitin-mediated degradation, including the ubiquitin ligase Ufd2 [6, 28]. We thus tested 
whether our UBL mutants retain their ability to interact with Ufd2.  We used bacterially 
expressed and purified GST-Ufd2 and Rad23 proteins in GST-pulldown experiments, following 
which the bound Rad23 proteins were detected by Western blotting for Rad23. As expected, 
wild-type Rad23 bound to GST-Ufd2 but not to GST alone, whereas Rad23∆UBL did not bind to 
GST-Ufd2 (Figure 4). Interestingly, Ufd2-binding was significantly reduced by the mutation of 
F9, but not of K43 or of S73. This finding suggests that hydrophobic interactions govern Ufd2 
binding to Rad23, and that the surfaces of Rad23 bound by Ufd2 and the proteasome do indeed 
overlap partially.  
 
UBA-binding mutations in the Rad23 UBL domain impair recruitment of a model 
substrate to the proteasome 
 
The degradation of ubiquitinated substrates by proteasomes is tightly coupled to their 
deubiquitination by the metalloisopeptidase activity of the Rpn11 subunit [29, 30]. The 
deubiquitinating activity of Rpn11 can be unmasked in vitro in the presence of a 20S proteolytic 
inhibitor such as epoxomicin, and can be used as a functional readout for recruitment of model 
ubiquitinated substrates to purified 26S proteasomes [31]. Therefore, we used the CDK inhibitor 
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Sic1 as a substrate in an in vitro deubiquitination assay to determine the ability of each Rad23 
UBL mutant to target ubiquitinated substrates to the proteasome.  
 
In this assay, ubiquitinated MbpSic1 is prepared with SCF complex (Figure 5 lane 1, which 
represents 100% pre-formed ubiquitinated substrate). Upon the addition of Rad23-deficient 
purified proteasomes, the ubiquitinated MbpSic1 is targeted to the proteasome and 
deubiquitinated.  Prior treatment of the proteasomes with epoxomicin inhibits substrate 
degradation and the extent to which deubiquitination occurs may be assessed by Western blotting 
for Sic1.  
 
As shown in Figure 5, the proteasome exhibited basal deubiquitinating activity in the absence of 
wild-type Rad23. Sic1 deubiquitination increased in the presence of wild-type Rad23 (lanes 3 
and 4), most likely due to the ability of Rad23 to facilitate delivery of ubiquitinated Sic1 to the 
proteasome. Sic1 deubiquitination was blocked by Rad23~∆UBL (lane 5) and limited to the 
basal level in the presence of the F9E/K43E mutant, which showed no detectable binding to the 
proteasome (Figure 3). In contrast, Sic1 deubiquitination was enhanced by the S73E mutant, 
which retained proteasome-binding (Figure 3). These results directly correlate deubiquitination 
with the ability of Rad23 to deliver ubiquitinated substrates to the proteasome.  
 
Discussion        
Interactions involving UBL and UBA domains are crucial to the function of the Rad23 family of 
proteins in ubiquitin-mediated protein degradation. In HHR23A, the intramolecular binding 
between the UBL and UBA domains is affected by and regulates interaction with other proteins 
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[18]. We show that disruption of the intramolecular UBL-UBA binding facilitates HHR23A 
interaction with polyubiquitin. Our data support the model that binding to either proteasomes or 
polyubiquitin disrupts the UBL-UBA interaction, causing HHR23A to adopt an open 
conformation that facilitates its interaction with polyubiquitinated proteins or proteasomes 
respectively. This coupling of proteasome-binding and substrate-binding renders the Rad23 
family more efficient in docking ubiquitinated substrates with the proteasome. Indeed, ubiquitin 
chains have been shown to enhance Rad23 binding to the proteasome in vivo [32]. Also, UBL-
UBA domain interactions may enhance specificity by blocking interactions that are weaker than 
the intramolecular UBL-UBA interaction. 
 
The UBA-binding surface of the Rad23/HHR23A UBL domain also mediates binding to the 
proteasomal subunit S5a as well as to other proteins such as the ubiquitin ligase Ufd2. We had 
targeted residues on the edge of the UBA-binding surface in an attempt to minimize disrupting 
other interactions but our mutations also affected proteasome-binding and Ufd2-binding. Our 
results are consistent with a previous report suggesting that the binding surfaces on the UBL 
domain for Ufd2 and the proteasome may overlap [28]. The difficulty of specifically disrupting 
interaction with only one protein without affecting others suggests that these different binding 
surfaces overlap significantly on the UBL domain and that the various interactions may regulate 
one another. The use of the same surface on Rad23/HHR23A for both proteasome- and Ufd2-
binding is consistent with a model in which Rad23 first binds ubiquitin conjugates associated 
with Ufd2, then dissociates from Ufd2 and binds the proteasome, to which the ubiquitin 
conjugates are thus delivered. This model contrasts with one in which Rad23 bridges Ufd2 and 
the proteasome by binding them simultaneously.  
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The UBL mutants tested constitute an allelic series, with the S73E mutant behaving most 
similarly to the wild-type UBL, following by K43E and then F9E. Despite the lack of detectable 
proteasome-binding in the native gel assay, which is based on fractionation of the interacting 
species, the UBL mutants possess sufficient residual affinity that they can still interact 
functionally with proteasomes, as evidenced by the deubiquitination of Sic1. Rad23∆UBL does 
not interact with proteasomes, yet it inhibited deubiquitination of Sic1. This dominant negative 
effect arises from a sequestering mechanism, as Rad23∆UBL can still bind ubiquitin chains and 
thus interfere with recognition by intrinsic ubiquitin receptors and other shuttling factors. In 
contrast, Sic1 was deubiquitinated in the presence of the UBL mutants in a manner that is 
consistent with each mutant’s relative ability to bind proteasomes. These data indicate that the 
capacity of Rad23 to bind proteasomes is essential for the ability of Rad23 family proteins to 
target ubiquitinated substrates to the proteasome. This model contrasts one in which ubiquitin 
chains bind the proteasome directly.  
 
Interestingly, HHR23A does not dimerize [18] whereas Rad23 does so in a manner that involves 
the C-terminal UBA domain [33, 34]. Rad23 can also heterodimerize with other UBL-UBA 
proteins such as Ddi1 [33, 34] while HHR23A interacts with hPLIC2 [35]. Therefore, 
intermolecular UBL-UBA domain interactions may also play a regulatory role in the recruitment 
of ubiquitinated substrates to the proteasome. 
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Conclusions 
In conclusion, both the intramolecular as well as intermolecular interactions of the UBL and 
UBA domains are important for the function of Rad23 family proteins in the ubiquitin-
proteasome pathway. In this study we have shown that physical interactions between the UBL 
and UBA domains couple proteasome binding via the UBL domain with ubiquitin-binding via 
the UBA domain, thus priming Rad23/HHR23A for its role in shuttling ubiquitinated substrates 
to the proteasome.  
 
Methods 
Plasmids  
For bacterial expression, proteins were cloned into either pGEX-6p-1 (Pharmacia) or pET-23a 
(Novagen). Where applicable, the FLAG tag was inserted by QuikChange-XL mutagenesis 
(Stratagene). We used pGEX2TK-based plasmids to express Rad23 and Rad23∆UBL proteins 
for radiolabelling [7]. HHR23A (GenBank:P54725), HHR23A UBL mutants, HHR23B 
(GenBank:P54727), and Rad23 (GenBank:P32628) UBL mutants were cloned into “pGEX-
6pK,” in which the heart muscle kinase recognition site present in pGEX-2TK was inserted 
upstream of the pGEX-6p-1 multiple cloning site by QuikChange-XL mutagenesis (Stratagene). 
The GST-Ufd2-myc plasmid has been previously described [28].  
 
Protein expression and purification 
Protein expression was induced in BL21(DE3) bacteria with 0.4mM isopropyl β-D-
thiogalactoside (IPTG) for 4 hours at 37°C. For GST-fusion protein purification, bacteria were 
lysed by sonication in PBS containing 2mM DTT, protease inhibitor cocktail (Roche), and 1% 
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Triton X-100. The proteins were purified on glutathione-sepharose beads and either eluted with 
10mM reduced glutathione in 50mM Tris-HCl pH 8.0 or cleaved from the resin-bound GST with 
PreScission protease (pGEX-6p1 proteins) or thrombin (pGEX-2TK proteins) according to the 
manufacturer’s instructions. For the purification of polyhistidine-tagged proteins, the bacteria 
were lysed in 25mM sodium phosphate pH 8, 300mM NaCl, 10mM imidazole, 2mM DTT and 
protease inhibitor cocktail (Roche). The polyhistidine-tagged proteins were bound to Ni-NTA 
resin (QIAGEN), washed with 50mM sodium phosphate pH 6.0, 300mM NaCl and 20mM 
imidazole. The proteins were then eluted with 25mM Tris-HCl pH 8, 300mM NaCl, 2mM DTT 
and 0.25M imidazole. Purified proteins were dialyzed overnight against PBS, 10% glycerol and 
2mM DTT. Protein purity was verified by SDS-PAGE analysis and Coomassie Blue staining.  
 
Free polyubiquitin chains were synthesized in vitro by incubating 100nM E1 (Boston Biochem), 
10µM E2-25K (Boston Biochem), and 40µg ubiquitin (Sigma) with 25mM Tris-HCl pH 7.6, 
50mM NaCl, 0.1mM DTT, 5mM MgCl2, 4mM ATP (Sigma), 0.03mg/ml creatine kinase, 5mM 
creatine phosphate, and 0.3unit/ml pyrophosphatase, at 30°C for 2 hours.  
 
Affinity column chromatography 
Glutathione sepharose was saturated with purified GST-HHR23A~∆UBL. The charged resin was 
then loaded into a 10ml HR10/10 (Pharmacia) column. 1µg each of wild-type UBL-His and 
mutated UBL-FLAG were mixed and loaded onto the GST-HHR23A~∆UBL column, following 
which the column was developed in PBS. 0.5ml fractions were collected, resolved by SDS-
PAGE and the proteins were detected by Western blotting. Antibodies used included anti-FLAG 
M2 monoclonal antibody (Sigma), anti-HA 12CA5 monoclonal antibody (produced in our lab), 
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and anti-polyhistidine affinity-purified rabbit polyclonal antibody (Rockland). Use of the 
Odyssey Imaging System (LI-COR Biotechnology) enabled each protein to be visualized 
simultaneously but distinctly.  
 
Competition assay to assess polyubiquitin-binding 
GST-HHR23A, untagged mutant variants of GST-HHR23A, free polyubiquitin chains and 
glutathione-sepharose beads were mixed for 1-2 hours at 4°C in binding buffer (20mM Tris-HCl 
pH 7.2, 150mM NaCl, 2mM EDTA, 2% (v/v) glycerol, 1mM DTT) [14] supplemented with 1% 
BSA. The resin was washed with binding buffer supplemented with 0.5% NP40. Proteins were 
eluted from the glutathione-sepharose resin and analyzed by Western blotting for polyubiquitin 
(FK2 monoclonal antibody, Affiniti Research Products). The band corresponding to tetra-
ubiquitin was quantified with a Biorad Fluor-S Max phosphoimager. Total binding was defined 
as the amount of polyubiquitin bound to the GST-HHR23A in the absence of competitor.  
Native gel assays for proteasome-binding 
Proteasomes were purified from S. cerevisiae as previously described [7]. All Rad23/HHR23 
proteins were bacterially expressed, purified on glutathione-sepharose beads, and labelled in 
vitro with [γ-32P]ATP (NEN) and heart muscle kinase according to the manufacturer’s 
instructions (Pharmacia Biotech). The radiolabelled proteins were cleaved from the resin with 
thrombin or PreScission protease, then quantified by scintillation counting and by Bradford 
assay. The specific activities of the proteins were normalized and mixed with proteasomes in a 
1:50, 1:20, and 1:10 molar excess of proteasome over proteins. After incubation at 30°C for 15 
minutes, the mixtures were resolved by 3.5% native PAGE essentially as previously described 
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[7, 36], though electrophoresis was carried out for 5 hours and the proteins visualized by 
autoradiography. 
 
GST-pulldown assay for Ufd2-binding 
Glutathione sepharose was saturated with purified GST-Ufd2. Purified Rad23 proteins were then 
added together with 50mM HEPES pH 7.5, 150mM NaCl, 5mM EDTA, 2% Triton X-100, 
0.2mg/ml BSA, and protease inhibitor cocktail (Roche). After mixing at 4°C for 60 minutes, the 
resin was washed with PBS and 0.1% Tween-20. The resin-bound Rad23 proteins were detected 
by Western blotting using an antibody against Rad23 (a gift from Kiran Madura).  
In vitro deubiquitination assay – The in vitro deubiquitination assay was performed as 
previously described [5]. Essentially, proteasomes were purified from Rad23-deficient S. 
cerevisiae and preincubated with 100µM epoxomicin for 45 minutes at 30°C to inhibit the 
protease activity of the proteasome. Ubiquitinated MbpSic1 was then added to the proteasome 
and its deubiquitination was analyzed by Western blotting for Sic1. Rad23 was added to the 
deubiquitination assay where indicated. 
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Figures 
Figure 1. Glutamic acid mutations in the UBL domain reduce binding to the UBA 
domains 
(A) The electrostatic potential is mapped onto the surface diagram of the UBL domain of 
HHR23A. Positive and negative charges are indicated by blue and red respectively. GRASP was 
used to generate the surface diagram, using the parameters -25.4 to -12.7 and 25.4 to 12.7 kT to 
generate the surface potentials. (B) The ribbon diagram of the UBL domain of HHR23A was 
generated with MOLMOL [37], using reported UBL domain coordinates for HHR23A. (C) 
Equal amounts of wild-type UBL-His and mutated UBL-FLAG were loaded onto a GST-
HHR23A~∆UBL column. The column was developed with PBS and fractions were collected for 
analysis by Western blotting, using antibodies against each epitope tag. Visualization of the 
proteins was performed with LI-COR’s Odyssey Imaging System. 
 
Figure 2.  HHR23A mutations that disrupt the UBL-UBA interaction enhance 
ubiquitin-binding 
 (A) GST-HHR23A, untagged mutant HHR23A, free polyubiquitin chains, and glutathione-
sepharose beads were mixed together. After the resin was washed, the bound proteins were 
eluted and resolved by SDS-PAGE and Western blotting performed with an antibody against 
polyubiquitin. While all the bands are conjugates of free ubiquitin, the arrow indicates that which 
corresponds to tetraubiquitin. (B) The band corresponding to tetraubiquitin was quantified with a 
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Biorad Fluor-S Max phosphoimager and data from a representative experiment are presented 
here.  
 
Figure 3.  Rad23 UBL mutants show no detectable interaction with the proteasome in 
vitro 
All Rad23 constructs were bacterially expressed, purified and radiolabelled with [γ-32P]ATP in 
vitro via an N-terminal HMK site. After quantification by scintillation counting and by Bradford 
assay, the radiolabelled proteins were normalized by counts and mixed with purified yeast 
proteasomes in a 1:10, 1:20 and 1:50 molar excess of proteasome over proteins. After incubation 
at 30°C for 15 minutes, the mixtures were electrophoresed on a 3.5% native gel at 100V for 5 
hours at 4°C. The arrows indicate free Rad23 proteins and the triangles indicate bands 
corresponding to proteasome-bound Rad23 proteins. “I/P” denotes the lane containing the input 
radiolabelled protein without any proteasome. 
 
Figure 4. Mutation of Rad23 F9 reduces interaction with Ufd2 
GST-pulldown experiments were performed by mixing each purified Rad23 protein with GST-
Ufd2 bound to glutathione-sepharose beads. After mixing at 4°C for 1 hour, the resin was 
washed, and bound proteins were eluted and analyzed by SDS-PAGE and Western blotting for 
Rad23. 
 
Figure 5. Mutation of the Rad23 UBL domain impairs proteasomal targeting 
Recombinant Sic1 was ubiquitinated in vitro, proteasomes lacking Rad23 were treated with 
epoxomycin, and the two were then incubated at 30°C in the absence or presence of purified 
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Rad23 proteins for 45 minutes. Deubiquitination of Sic1 was then analyzed by Western blotting 
for Sic1.   
 
Additional files 
 
Additional file 1. Retention of proteins on the GST-HHR23A~∆UBL column corresponds 
to their ability to interact with UBA domains 
(A) Purified GST-HHR23A~∆UBL protein was used to saturate glutathione-sepharose resin, 
which was in turn used to pack an HR10/10 column. Equal amounts of HA-tagged SUMO (HA-
SUMO), polyhistidine-tagged ubiquitin (Ub-His) and FLAG-tagged UBL (UBL-FLAG) were 
loaded simultaneously onto the column and the column was resolved in PBS. Fractions were 
collected and analyzed by Western blotting using epitope-specific antibodies. (B) Purified GST 
was bound to glutathione-sepharose resin in excess, which was then used to pack an HR10/10 
column. Equal amounts of HA-SUMO, Ub-His and UBL-FLAG were mixed, loaded onto the 
column and analyzed as described above.  
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